PMID- 31305297
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20200918
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 30
IP  - 7
DP  - 2019 Aug
TI  - Efficacy and safety of apatinib in advanced sarcoma: an open-label, 
      nonrandomized, single-center study of 45 patients.
PG  - e0778
LID - 10.1097/CAD.0000000000000778 [doi]
AB  - Sarcoma is a rare tumor with more than 50 histologic subtypes. Patients with 
      advanced sarcoma have a poor prognosis. The aim of this study was to evaluate the 
      efficacy and safety of apatinib, an oral vascular endothelial growth factor 
      receptor-2 inhibitor, as salvage treatment for advanced bone and soft tissue 
      sarcomas. From May 2017 to July 2018, a prospective, open-label, nonrandomized, 
      clinical trial of apatinib was carried out in selected patients with advanced 
      sarcoma. After apatinib dosing, progression-free survival (PFS), overall survival 
      (OS), objective response rate, disease control rate, and treatment-related 
      adverse events (AEs) were reviewed and evaluated. Patients were administered 
      apatinib for at least 1 month. Median follow-up time was 6.00 months (1-13 
      months). The median PFS was 7.88 months, with the longest PFS of 13 months 
      observed in a patient with epithelial sarcoma. The 3-month PFS rate was 66.44%. 
      The median OS was 11.64 months with significant differences observed based on 
      disease subtypes. Four patients achieved a partial response, and 36 patients 
      achieved stable disease. The objective response rate was 8.88% (4/45), and the 
      disease control rate was 88.89% (40/45). The most common grade 3/4 
      treatment-related AEs were hypertension (12.50%), hand-foot syndrome (6.67%), 
      diarrhea (12.50%), fatigue (6.25%), and proteinuria (14.29%). One drug-related 
      severe AE of thrombocytopenia (21x10/l) occurred 2 months after therapy. Apatinib 
      treatment in our study exhibited objective efficacy in PFS, OS, and manageable 
      toxicity in patients with advanced sarcoma. This result supports future 
      randomized controlled trials to further define apatinib activity in stage IV 
      sarcomas.
FAU - Weitao, Yao
AU  - Weitao Y
AD  - Bone and Soft Department, the Affiliated Cancer Hospital of Zheng Zhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
FAU - Fangxing, Wu
AU  - Fangxing W
FAU - Qiqing, Cai
AU  - Qiqing C
FAU - Jiaqiang, Wang
AU  - Jiaqiang W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Non-Randomized Controlled Trials as Topic
MH  - Prognosis
MH  - Prospective Studies
MH  - Pyridines/*therapeutic use
MH  - Sarcoma/*drug therapy/pathology
MH  - Survival Rate
MH  - Young Adult
EDAT- 2019/07/16 06:00
MHDA- 2020/09/20 06:00
CRDT- 2019/07/16 06:00
PHST- 2019/07/16 06:00 [entrez]
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
AID - 00001813-201908000-00013 [pii]
AID - 10.1097/CAD.0000000000000778 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2019 Aug;30(7):e0778. doi: 10.1097/CAD.0000000000000778.